

With your courage and our science, we're weaving new possibilities in Alzheimer's disease research

Introducing the CELIA clinical trial for people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia

The CELIA clinical trial is researching a potential treatment for people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia by focusing on a protein called **tau**. Abnormal tangles of built-up tau protein can be considered a key sign of the disease. **We want to understand if different doses of a study drug called BIIB080 could be safe and have an effect on the progression of Alzheimer's disease.**

We understand that you have been working to navigate an Alzheimer's disease diagnosis. Your next step on this journey could be the CELIA trial.

Could you take part?

We are looking for about **735 people** who:

- Have mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer's disease dementia
- Are 50 to 80 years old
- Have a **care partner** (sometimes called a study partner) who agrees to support you throughout the trial

Other criteria apply and your study team will explain these to you.



The link between tau and Alzheimer's disease

Alzheimer's disease is hallmarked by two proteins—**amyloid plaques** and **tau tangles**.



Beta-amyloid fragments cluster together into larger deposits called **amyloid plaques**. The plaques appear to have a toxic effect on neurons (nerve cells), which stops messages from passing between cells.



Tau proteins change shape and form tangles inside neurons—commonly known as **tau tangles**—compromising the normal function and health of neurons. When neurons are damaged, the brain cannot send messages as easily, causing some of the symptoms of Alzheimer's disease like confusion, forgetfulness, and behavior changes.

That's why the CELIA trial is researching a study drug that aims to reduce the production of tau in order to understand if it could have an effect on the progression of Alzheimer's disease, potentially slowing down symptoms of the disease.

247AD201_Study flyer_v1_18Feb22_US (English)
Biogen-155963

Safety is our priority

As with all clinical trials, your health and safety are our top priority. If your health gets worse during this clinical trial, your study team will discuss options with you. You can leave the trial at any time without affecting your usual medical care.

Ready to learn more about the CELIA clinical trial for Alzheimer's disease?

Reach out to the study team:

Mary S. Easton Center for Alzheimer's
Research & Care, UCLA
Lorena Macias
(310)-794-6191

For more information about clinical trials and Biogen's research in Alzheimer's disease, visit [BiogenTrialLink.com](https://www.biogen.com/clinical-trials).

